Protosappanin A

• Target :

  NF-?B|||HIV Protease|||I?B/IKK|||NADPH-oxidase|||IL Receptor|||JAK|||COX|||STAT|||ROS|||Interleukin|||TLR|||TNF|||NO Synthase

• Related Pathways :

  Neuroscience|||Microbiology/Virology|||NF-?B|||Tyrosine Kinase/Adaptors|||Stem Cells|||Chromatin/Epigenetic|||Apoptosis|||Proteases/Proteasome|||JAK/STAT signaling|||Immunology/Inflammation|||Angiogenesis

• Purity :

  >99.99%

• Bioactivity :

  Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.

• Smiles :

  Oc1ccc-2c(OCC(=O)Cc3cc(O)c(O)cc-23)c1

• Molecular Formula :

  C15H12O5

• Molecular Weight :

  272.25

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  102036-28-2